In the setting of ST-segment elevation myocardial infarction (STEMI), patients at high risk of
systemic emboli who undergo primary percutaneous coronary intervention (PCI) using …

Background Dual antiplatelet therapy is usually superior to mono therapy in preventing
recurrent vascular events (VEs). This systematic review assesses the safety and efficacy of …

Background There are no reported randomized controlled trials of triple antithrombotic
therapy (TT; aspirin plus a thienopyridine plus vitamin K antagonist) vs dual antiplatelet …

Antithrombotic therapy is an essential component in the optimisation of clinical outcomes in
patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous …

Aims: Rates of stent thrombosis (ST) after ST-elevation myocardial infarction (STEMI) may
vary over time and the relationship of this complication with non-adherence to dual …

Background—Whether triple antiplatelet therapy is superior or similar to dual antiplatelet
therapy in patients with acute ST-segment elevation myocardial infarction undergoing …

The first three hours after symptom onset hold the maximum potential for myocardial
reperfusion and salvage in ST-elevation myocardial infarction (STEMI) patients. During this …

Background: The risk of recurrent ischemic and bleeding events after primary percutaneous
coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) may not …

Greater use of evidence-based therapies has improved outcomes for patients with acute
coronary syndromes (ACS) in recent decades. Consequently, more ACS patients are …

Objectives: The aim of this study was to compare clinical outcomes in relation to the duration
of triple antithrombotic therapy (TAT) among patients with indications for oral anticoagulation …